$1.46
+0.03 (+2.10%)
Open$1.47
Previous Close$1.43
Day High$1.47
Day Low$1.44
52W High$2.86
52W Low$0.96
Volume—
Avg Volume4.57M
Market Cap252.69M
P/E Ratio—
EPS$-0.64
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+201.4% upside
Current
$1.46
$1.46
Target
$4.40
$4.40
$2.36
$4.40 avg
$4.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.39M | 123.33M | 94.21M |
| Net Income | 12.19M | 12.43M | 9.10M |
| Profit Margin | 10.5% | 10.1% | 9.7% |
| EBITDA | 16.58M | 20.40M | 14.08M |
| Free Cash Flow | 11.50M | 12.12M | 8.26M |
| Rev Growth | -3.2% | +20.3% | +7.0% |
| Debt/Equity | 0.59 | 0.58 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $262.82 | +1.11% | 72.8 | 459.33B |
| AMGN | Amgen Inc | $403.04 | -1.04% | 25.1 | 219.33B |
| GILD | Gilead Sciences Inc | $144.74 | -1.87% | — | 179.15B |
| VRTX | Vertex Pharmaceuticals Inc | $504.73 | -0.40% | 30.1 | 132.51B |
| REGN | Regeneron Pharmaceuticals | $735.20 | +0.05% | 17.4 | 75.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.72 | -4.96% | 36.9 | 29.82B |